# US 2017/0281771 A1 · Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281771 A1
- Document ID: US20170281771A1
- Status: Published application
- Kind: A1
- Application number: 15/462,643
- Filed: 2017-03-17
- Published: 2017-10-05
- Earliest claimed: 2001-12-07
- Assignees: Cytori Therapeutics, Inc.
- Applicants: Cytori Therapeutics, Inc.
- Inventors: John K. Fraser; Marc H. Hedrick; Min Zhu; Brian M. Strem; Eric Daniels; Isabella Wulur
- Web page: https://patentgrep.com/patent/US20170281771A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C12N 5/0653: {Adipocytes; Adipose tissue}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g., stem and/or progenitor cells, obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, adipose derived regenerative cells are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.

## Claims

### Claim 1

A method for treating a disorder characterized by insufficient cardiac function in a subject, comprising administering to the subject a composition comprising adipose derived cells, such that the disorder is treated.
